<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02480933</url>
  </required_header>
  <id_info>
    <org_study_id>CentroHLO</org_study_id>
    <nct_id>NCT02480933</nct_id>
  </id_info>
  <brief_title>Silent Breast Cancer A Study of the Disease Prevalence Held by Imaging Guided Biopsies in Autopsy Specimens</brief_title>
  <acronym>SISYPHUS</acronym>
  <official_title>Silent Breast Cancer A Study of the Disease Prevalence Held by Imaging Guided Biopsies in Autopsy Specimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Hospitalar Lisboa Ocidental</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Nacional de Medicina Legal e Ciências Forenses, Delegação do Sul</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centro Hospitalar Lisboa Ocidental</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to define silent breast cancer prevalence in both sexes and will be
      held by biopsies performed in imaging suspicious areas of the breast (ecography and
      mammography) in cadavers without known breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cadavers of both sexes are going to be submitted to bilateral mastectomy. The specimens are
      going to be examined by palpation, ecography and mammography and all areas with (Breast
      Imaging Reporting and Data System) BI-RADS classification &gt;= 3 are going to be biopsied.

      Biopsy specimens are going to be processed by the pathology department and cancers are going
      to be identified and classified by their molecular type.

      The investigators intend to know which is the disease reservoir in various ages.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Silent breast cancer prevalence</measure>
    <time_frame>2 years</time_frame>
    <description>To define the existing disease that did not caused death in both sexes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Silent breast cancer prevalent molecular profile</measure>
    <time_frame>2 years</time_frame>
    <description>To identify those molecular subgroups of the disease that remain silent</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">768</enrollment>
  <condition>Female Breast Cancer</condition>
  <condition>Male Breast Cancer</condition>
  <arm_group>
    <arm_group_label>female cadavers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>female cadavers above 40 years without known breast cancer Bilateral mastectomy Biopsy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Male cadavers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>male cadavers above 40 years without known breast cancer Bilateral mastectomy Biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bilateral mastectomy</intervention_name>
    <description>Bilateral mastectomy and imaging study of cadaveric breasts</description>
    <arm_group_label>female cadavers</arm_group_label>
    <arm_group_label>Male cadavers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biopsy</intervention_name>
    <description>Biopsy of BI-RADS 3 and superior lesions</description>
    <arm_group_label>female cadavers</arm_group_label>
    <arm_group_label>Male cadavers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female and male cadavers above 40 years

        Exclusion Criteria:

          -  Known breast cancer

          -  Breast tissue accidental damage
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2015</study_first_submitted>
  <study_first_submitted_qc>June 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2015</study_first_posted>
  <last_update_submitted>November 24, 2017</last_update_submitted>
  <last_update_submitted_qc>November 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centro Hospitalar Lisboa Ocidental</investigator_affiliation>
    <investigator_full_name>Zacharoula Sidiropoulou</investigator_full_name>
    <investigator_title>Zacharoula Sidiropoulou MD, MSc, Principal Investigator, General Surgery Assistent</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms, Male</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>https://doi.org/10.3892/mco.20</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://www.spandidos-publications.com/mco</doc_url>
      <doc_comment>feasibility of the protocol paper</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

